212 related articles for article (PubMed ID: 32770099)
21. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.
Nadeu F; Martin-Garcia D; Clot G; Díaz-Navarro A; Duran-Ferrer M; Navarro A; Vilarrasa-Blasi R; Kulis M; Royo R; Gutiérrez-Abril J; Valdés-Mas R; López C; Chapaprieta V; Puiggros M; Castellano G; Costa D; Aymerich M; Jares P; Espinet B; Muntañola A; Ribera-Cortada I; Siebert R; Colomer D; Torrents D; Gine E; López-Guillermo A; Küppers R; Martin-Subero JI; Puente XS; Beà S; Campo E
Blood; 2020 Sep; 136(12):1419-1432. PubMed ID: 32584970
[TBL] [Abstract][Full Text] [Related]
22. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.
Kridel R; Meissner B; Rogic S; Boyle M; Telenius A; Woolcock B; Gunawardana J; Jenkins CE; Cochrane C; Ben-Neriah S; Tan K; Morin RD; Opat S; Sehn LH; Connors JM; Marra MA; Weng AP; Steidl C; Gascoyne RD
Blood; 2012 Mar; 119(9):1963-71. PubMed ID: 22210878
[TBL] [Abstract][Full Text] [Related]
23. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and
Rodrigues JM; Hollander P; Schmidt L; Gkika E; Razmara M; Kumar D; Geisler C; Grønbæk K; Eskelund CW; Räty R; Kolstad A; Sundström C; Glimelius I; Porwit A; Jerkeman M; Ek S
Haematologica; 2024 Apr; 109(4):1171-1183. PubMed ID: 37646663
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
[TBL] [Abstract][Full Text] [Related]
25. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
[TBL] [Abstract][Full Text] [Related]
26. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
[TBL] [Abstract][Full Text] [Related]
27. p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.
Rodrigues JM; Hassan M; Freiburghaus C; Eskelund CW; Geisler C; Räty R; Kolstad A; Sundström C; Glimelius I; Grønbaek K; Kwiecinska A; Porwit A; Jerkeman M; Ek S
Br J Haematol; 2020 Dec; 191(5):796-805. PubMed ID: 32748433
[TBL] [Abstract][Full Text] [Related]
28. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.
Meissner B; Kridel R; Lim RS; Rogic S; Tse K; Scott DW; Moore R; Mungall AJ; Marra MA; Connors JM; Steidl C; Gascoyne RD
Blood; 2013 Apr; 121(16):3161-4. PubMed ID: 23407552
[TBL] [Abstract][Full Text] [Related]
29. Gene mutations and actionable genetic lesions in mantle cell lymphoma.
Ahmed M; Zhang L; Nomie K; Lam L; Wang M
Oncotarget; 2016 Sep; 7(36):58638-58648. PubMed ID: 27449094
[TBL] [Abstract][Full Text] [Related]
30. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.
Halldórsdóttir AM; Lundin A; Murray F; Mansouri L; Knuutila S; Sundström C; Laurell A; Ehrencrona H; Sander B; Rosenquist R
Leukemia; 2011 Dec; 25(12):1904-8. PubMed ID: 21720382
[No Abstract] [Full Text] [Related]
31. Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.
Rodrigues JM; Porwit A; Hassan M; Ek S; Jerkeman M
Leuk Lymphoma; 2021 Nov; 62(11):2637-2647. PubMed ID: 34080947
[TBL] [Abstract][Full Text] [Related]
32. Characterization of 4 mantle cell lymphoma cell lines.
Amin HM; McDonnell TJ; Medeiros LJ; Rassidakis GZ; Leventaki V; O'Connor SL; Keating MJ; Lai R
Arch Pathol Lab Med; 2003 Apr; 127(4):424-31. PubMed ID: 12683869
[TBL] [Abstract][Full Text] [Related]
33. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.
Aukema SM; Hoster E; Rosenwald A; Canoni D; Delfau-Larue MH; Rymkiewicz G; Thorns C; Hartmann S; Kluin-Nelemans H; Hermine O; Dreyling M; Klapper W
Blood; 2018 Jan; 131(4):417-420. PubMed ID: 29196411
[TBL] [Abstract][Full Text] [Related]
34. Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Ravcukova B; Vasova I; Muzik J; Malcikova J; Falkova I; Slovackova J; Smardova J
Int J Oncol; 2010 Mar; 36(3):699-706. PubMed ID: 20126990
[TBL] [Abstract][Full Text] [Related]
35. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.
Che Y; Liu Y; Yao Y; Hill HA; Li Y; Cai Q; Yan F; Jain P; Wang W; Rui L; Wang M
Blood Cancer J; 2023 Feb; 13(1):27. PubMed ID: 36797243
[TBL] [Abstract][Full Text] [Related]
36. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma.
Fang NY; Greiner TC; Weisenburger DD; Chan WC; Vose JM; Smith LM; Armitage JO; Mayer RA; Pike BL; Collins FS; Hacia JG
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5372-7. PubMed ID: 12697903
[TBL] [Abstract][Full Text] [Related]
37. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Delfau-Larue MH; Klapper W; Berger F; Jardin F; Briere J; Salles G; Casasnovas O; Feugier P; Haioun C; Ribrag V; Thieblemont C; Unterhalt M; Dreyling M; Macintyre E; Pott C; Hermine O; Hoster E;
Blood; 2015 Jul; 126(5):604-11. PubMed ID: 26022239
[TBL] [Abstract][Full Text] [Related]
38. Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy.
Karolová J; Kazantsev D; Svatoň M; Tušková L; Forsterová K; Maláriková D; Benešová K; Heizer T; Dolníková A; Klánová M; Winkovska L; Svobodová K; Hojný J; Krkavcová E; Froňková E; Zemanová Z; Trněný M; Klener P
Am J Hematol; 2023 Oct; 98(10):1627-1636. PubMed ID: 37605345
[TBL] [Abstract][Full Text] [Related]
39. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
[TBL] [Abstract][Full Text] [Related]
40. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.
Yi S; Yan Y; Jin M; Bhattacharya S; Wang Y; Wu Y; Yang L; Gine E; Clot G; Chen L; Yu Y; Zou D; Wang J; Phan AT; Cui R; Li F; Sun Q; Zhai Q; Wang T; Yu Z; Liu L; Liu W; Lyv R; Sui W; Huang W; Xiong W; Wang H; Li C; Xiao Z; Hao M; Wang J; Cheng T; Bea S; Herrera AF; Danilov A; Campo E; Ngo VN; Qiu L; Wang L
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 34882582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
